Skip to main content
Premium Trial:

Request an Annual Quote

Onegevity Health to Add Gencove's Low-Pass Genome Sequencing to Consumer Service

NEW YORK (GenomeWeb) – Consumer wellness startup Onegevity Health said today that it is incorporating Gencove's low-pass genome sequencing and analytics into its service.

Under the partnership, Gencove, a spinout from the New York Genome Center, will provide its low-pass sequencing solution to Onegevity's multi-omic artificial intelligence platform and services. 

Based on data analysis, New York-based Onegevity provides customers with recommendations for customized nutrition and supplements in order to improve their health. Its first product, GutBio, combines metagenomic sequencing with AI-based personalized recommendations to increase gut health. The company has a partnership with supplements company Thorne.

In addition, Onegevity and Gencove plan to use Onegevity's multi-omics database for research and therapeutic development, such as studies of rare genetic variants and drug target discovery.

"Gencove's low-pass sequencing technologies provide us with the opportunity to apply genome sequencing at the scale necessary to truly impact population health and also ensure the greatest capacity to integrate future discoveries in all areas of the genome," said Paul Jacobson, CEO of Thorne and a cofounder of Onegevity, in a statement.

Earlier this year, Gencove and SeqWell said they would integrate their respective sequencing and library preparation technologies. Also, last fall, Gencove teamed up with BGI Americas to join their technologies into a single service.